Chimeric Influenza HA Segments for High-Yield Cell Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing influenza vaccines face challenges in achieving high yields of reassortant influenza viruses, particularly in cell culture, where wild-type viruses grow to low titers and chimeric viruses with improved growth in eggs do not perform well.
Innovation Solution
Development of chimeric influenza hemagglutinin and neuraminidase segments with specific domain combinations from different influenza strains, optimized for improved growth in cell culture, including specific nucleotide and amino acid positions, to enhance viral yields.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If wild-type influenza viruses are used for vaccine production, then the vaccine maintains antigenic accuracy, but the viral yield in cell culture remains low
Solution Approach 1:
The patent applies local quality by creating chimeric HA segments where only specific domains (transmembrane and cytoplasmic) are replaced with sequences from high-yield donor strains, while the ectodomain maintaining antigenic accuracy remains from the vaccine strain. This localized modification allows the virus to gain improved growth properties without compromising the antigenic regions needed for vaccine efficacy.
Solution Approach 2:
The invention creates composite viral structures by combining genetic material from multiple sources: the HA segment contains the ectodomain from the vaccine strain combined with transmembrane and cytoplasmic domains from high-yield donor strains. This composite approach allows the reassortant virus to inherit both the antigenic properties of the vaccine strain and the high-yield growth characteristics of the donor strain.
2Productivity
If chimeric HA segments from A/PR/8/34 are used to improve egg growth, then egg substrate performance improves, but cell culture growth remains poor
Solution Approach 1:
The patent applies parameter changes by selecting specific amino acid sequences at critical positions (31-41 in the transmembrane domain and 1-23 in the cytoplasmic domain) that optimize cellular interactions and growth properties. By modifying these specific parameters in the HA segment based on sequences from high-yield donor strains, the reassortant viruses achieve improved growth in both egg and cell culture systems.
3Quantity of substance
If reassortment is performed to obtain high-yield donor strain characteristics, then viral growth improves, but the process complexity increases
Solution Approach 1:
The patent applies segmentation by focusing reassortment efforts on specific HA segment domains rather than attempting to optimize the entire viral genome. By identifying and reassorting only the critical transmembrane and cytoplasmic domains of the HA segment, the process becomes more manageable and targeted, reducing overall complexity while achieving the desired high-yield growth characteristics.
Data Source
AI summary
The invention provides reassortant influenza strains.